NADAC acquisition cost data for CABERGOLINE 0.5 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00093542088 | $2.01 | 2022-12-21 | Rx |
| 23155082373 | $2.01 | 2022-12-21 | Rx |
| 49884067314 | $2.01 | 2022-12-21 | Rx |
| 50742011808 | $2.01 | 2022-12-21 | Rx |
| 59762100501 | $2.01 | 2022-12-21 | Rx |
| 00093542088 | $2.01 | 2022-12-21 | Rx |
| 23155082373 | $2.01 | 2022-12-21 | Rx |
| 49884067314 | $2.01 | 2022-12-21 | Rx |
| 50742011808 | $2.01 | 2022-12-21 | Rx |
| 59762100501 | $2.01 | 2022-12-21 | Rx |
Generic: Cabergoline | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $7.9M | 53,207 | 15,601 | $10.97 |
| 2020 | $8.0M | 58,105 | 16,145 | $9.73 |
| 2021 | $9.2M | 73,280 | 17,176 | $8.44 |
| 2022 | $9.8M | 76,514 | 18,014 | $8.54 |
| 2023 | $8.6M | 81,164 | 19,362 | $7.10 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $732.4K | 7,966 | 2,030 |
| Florida | $717.4K | 6,378 | 1,665 |
| Texas | $609.0K | 5,446 | 1,491 |
| New York | $603.9K | 6,398 | 1,474 |
| Ohio | $391.5K | 2,910 | 717 |
| Pennsylvania | $378.4K | 3,490 | 883 |
| North Carolina | $318.4K | 2,983 | 724 |
| Illinois | $311.4K | 2,778 | 694 |
| New Jersey | $296.3K | 2,628 | 647 |
| Massachusetts | $252.0K | 2,622 | 625 |
| Michigan | $251.3K | 2,378 | 615 |
| Georgia | $246.4K | 2,322 | 642 |
| Virginia | $225.0K | 1,773 | 453 |
| Missouri | $208.5K | 1,590 | 372 |
| Wisconsin | $207.2K | 1,505 | 357 |
| Indiana | $202.7K | 1,536 | 362 |
| Puerto Rico | $184.5K | 3,173 | 537 |
| Tennessee | $184.1K | 1,720 | 432 |
| Arizona | $164.9K | 1,395 | 383 |
| Connecticut | $158.1K | 1,224 | 286 |
| Minnesota | $155.7K | 1,444 | 349 |
| Alabama | $153.5K | 1,294 | 320 |
| Kentucky | $151.8K | 1,357 | 296 |
| South Carolina | $130.1K | 1,150 | 301 |
| Washington | $126.4K | 1,381 | 347 |
| Louisiana | $125.3K | 1,266 | 285 |
| Maryland | $122.9K | 1,315 | 347 |
| Colorado | $117.8K | 1,024 | 269 |
| Oregon | $84.2K | 885 | 216 |
| Oklahoma | $82.9K | 687 | 165 |
| Kansas | $71.9K | 794 | 164 |
| Arkansas | $62.7K | 538 | 114 |
| Nevada | $60.1K | 506 | 142 |
| Idaho | $58.5K | 392 | 98 |
| Mississippi | $50.1K | 578 | 128 |
| Iowa | $48.5K | 474 | 101 |
| Utah | $46.7K | 417 | 125 |
| Nebraska | $46.3K | 363 | 87 |
| Maine | $42.7K | 327 | 87 |
| New Mexico | $39.7K | 357 | 100 |
| West Virginia | $38.0K | 380 | 82 |
| New Hampshire | $32.7K | 318 | 86 |
| South Dakota | $22.1K | 266 | 70 |
| Hawaii | $19.4K | 192 | 48 |
| District of Columbia | $18.0K | 171 | 46 |
| Rhode Island | $17.8K | 217 | 50 |
| Delaware | $16.6K | 216 | 52 |
| Montana | $15.7K | 197 | 49 |
| Vermont | $15.1K | 92 | 25 |
| North Dakota | $12.2K | 152 | 33 |
| Alaska | $9.5K | 91 | 21 |
| Wyoming | $3.1K | 63 | 17 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.